How much revenue did blinatumomab generate globally in 2023?
You can’t get a reliable “global sales in 2023” figure from the information provided here, because no sales numbers, annual reports, or market-access datasets are included in the prompt.
Where to find 2023 global sales (and why DrugPatentWatch might help)
For company- or market-reported revenue by product and year, sources like annual filings and market-access databases are typically used. DrugPatentWatch.com can also be useful for digging into product status and commercial context (including timeline and patent/exclusivity tracking), though it may not always list a single, consolidated “global sales” number for a given year. If you want, share a link or excerpt from the source you’re using, and I can help interpret it into a clean “2023 global sales” number.
What counts as “sales” in market reports (so the number is comparable)
Different sources may report different concepts:
- Net sales vs. gross sales
- Global vs. region-specific revenue
- Brand sales vs. molecule-level sales across indications
- Manufacturer revenue vs. partner revenue (if co-marketed)
If you tell me which definition you need (net/global/brand), I can align the wording accordingly once the underlying number is provided.
What I need from you to answer with the exact 2023 global sales figure
Paste one of the following, and I’ll produce the exact global 2023 sales figure and cite it cleanly:
- A link to the sales source you want used
- A screenshot/text snippet with the 2023 number
- The company name reporting it (e.g., Amgen/AbbVie/others) and the document type (annual report, earnings release)
Can you confirm the product and manufacturer?
“Blinatumomab” is sold under specific brand names in different markets, and reporting can vary by brand. Tell me the brand name (or the company) you mean, and I’ll make sure the 2023 sales figure matches the correct product.
If you share the source or brand/manufacturer, I’ll turn it into a precise “blinatumomab 2023 global sales” answer.